Advances in our molecular understanding of cancer mean we can selectively target specific patient profiles, leading to precision treatments in oncology. However, conducting clinical trials for sometimes rare subsets of patients can be logistically and technically challenging.
SPECTA (Screening cancer Patients for Efficient Clinical Trial Access) is a collaborative European platform that helps deliver high-quality, translational research across tumor types and molecular alterations.
The platform provides an integrated and shared mechanism, with rapid access to patient data and biological samples to enable the quick implementation of new clinical trials and robust translational research. It provides access to state-of-the-art technical services for biobanking and molecular profiling, ensuring research is efficient, reproducible, traceable, and high-quality.
For SPECTA, please enroll patients with the tumor type specified in the table, ONLY when the status is green. You can enroll those patients by clicking on the , next to the green status.
Study specific information (HBM, Project Specific selection criteria, CRF completion guidelines…) can be found here . Please note that your electronic database password is required for access.
For any questions, please contact the general SPECTA e-mail address: firstname.lastname@example.org.
|Lower Gastrointestinal Tract (LowGI)|
|Adenocarcinoma and Squamous
Carcinoma of the Colon and Rectum
|RP-1544||To be opened|
|Hepatobiliary System (HEPAT)|
|Cholangiocarcinoma||RP-1544||To be opened|
|Exocrine Pancreas||RP-1544||To be opened|
|Neuroendocrine Tumors (NET)|
|Neuroendocrine Tumors of the Stomach,
duodenum and Ampulla of Vater, Jejunum and
Ileum, Appendix, Colon and Rectum, Pancreas
|RP-1544||To be opened|
|Non Small Cell Lung Carcinoma||Lung Cancer Personalized Medicine||Open|
|Non-Grade 1 Bone Sarcoma||RP-1759 – AYA/TYA (12-29 years old)||To be opened|
|Non-Grade 1 Soft Tissue Sarcoma||RP-1759 – AYA/TYA (12-29 years old)
RP-1544 (≥ 18 years old)
|To be opened|
|Female Reproductive Organs (GeniF)|
|Ovarian Cancer||RP-1544||To be opened|
|Central Nervous system (CNS)|
|High Grade Diffuse Astrocytic Tumors||RP-1759 – AYA/TYA (12-29 years old)||To be opened|
Lung Cancer Personalized Medicine
Non Small Cell Lung Carcinoma patients with at least three months life-expectancy and 18 years or older
For this study, FFPE tissue will be collected at diagnosis, and used for NGS sequencing. After molecular tumor board validation, you will be informed if your patient is eligible for a specific targeted trial, such as:
- phase 2 STARTRK-2 clinical trial with Entrectinib (Ignyta trial) for patients with NTRK1/2/3, ROS1 or ALK gene rearrangements
- Phase 1 clinical trial with LOXO-292 for patients with RET-Fusion Lung Cancer
Blood will be collected at diagnosis and follow-up, and used as liquid biopsy to support the European funded project called Cancer-ID. The goal of this project is to develop/improve and standardize methods for liquid biopsy collection and analysis.
RP-1759 – AYA/TYA
12-29 year-old: Non-Grade 1 Bone and Soft Tissue Sarcoma , High Grade Diffuse Astrocytic Tumors patients
EORTC wants to develop a sequencing project targeting specifically young adults (12 to 29 years old) with rare cancer:
- to understand better the biology of the tumor in this specific population, and compare it to children and adults with similar disease
- to improve the inclusion of young adults into clinical trials.
The pilot study will be focusing on young adults with high grade glioma as well as non-grade 1 bone and soft tissue sarcoma. Patients must be recruited prospectively within 6 weeks of initial diagnosis, refractory disease or disease relapse. The aim of the pilot phase is to test the infrastructure and our accrual potential in this age group of patients.
For this project, we will collect FFPE tissue available at enrollment to perform NGS sequencing and also implement a central pathology review as well as a molecular tumor board, to bring the clinical knowledge back to the patient and the clinician.
Locally advanced or metastatic solid tumor:
Adenocarcinoma and Squamous Carcinoma of the Colon and Rectum patients, Soft Tissue Sarcoma, Cholangiocarcinoma, Neuroendocrine Tumors, Ovarian Cancer, Exocrine Pancreas
For this study, FFPE tissue available at enrollment will be collected, and used to screen for NTRK1/2/3, ROS1 or ALK gene rearrangement to assess eligibility for the STARTRK-2 clinical trial (Ignyta phase 2 trial for Entrectinib). You will then be informed if your patient is eligible for this trial.